Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
Outlook Therapeutics (OTLK) Stock Price & Analysis
1,117 Followers
OTLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.01 - $37.20
Previous Close$6.79
Volume176.91K
Average Volume (3M)719.73K
Market Cap
$158.92M
Enterprise Value$156.44M
Total Cash (Recent Filing)$47.23M
Total Debt (Recent Filing)$44.74M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 14, 2024EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.47
Shares Outstanding23,405,637
10 Day Avg. Volume252,387
30 Day Avg. Volume719,727
Standard Deviation0.37
R-Squared0.00839
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-6.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.38
Forecast
1Y Price Target
$35.00Price Target Upside415.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Outlook Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityWith its recent capital raise, the company has enough cash into mid-2025, indicating a strong financial position to support ongoing operations and growth.
Market PotentialThe commercial market for treating retinal diseases is sizable, and the company's ONS-5010 could tap into the annual sales potential of approximately $15 billion.
Regulatory ApprovalThe European Commission's approval of ONS-5010 under the brand name LYTENAVA applies to all 27 EU member states plus Iceland, Norway, and Liechtenstein.
Bears Say
EarningsEPS of $(1.55) compared with estimates of $(0.85) - (1.27).
Product ConcernsCompounded bevacizumab, despite its lower price, has concerns about manufacturing quality and potential adverse events.
Regulatory SetbacksFDA issued a Complete Response Letter (CRL) for the BLA for ONS-5010 due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $4.01 and its highest was $37.20 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Currently, no data Available
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 14, 2024 which is in 66 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2024. The company reported -$1.55 earnings per share for the quarter, missing the consensus estimate of -$0.91 by -$0.64.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -$1.03.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 23,405,638 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$1.55 in its last earnings report, missing expectations of -$0.91. Following the earnings report the stock price went down -1.346%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Among the largest hedge funds holding Outlook Therapeutics’s share is Wexford Capital LP. It holds Outlook Therapeutics’s shares valued at N/A.
---
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (415.46% Upside)
$35.00 (415.46% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $48.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.26%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Earnings Call
Q2 2024
0:00 / 0:00
---
OTLK Stock 12 Month Forecast
Average Price Target
$35.00
▲(415.46% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Minerva Neurosciences
―
ACADIA Pharmaceuticals
―
Kodiak Sciences
―
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-9.59%
reiterated a buy rating 19 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -9.59% per trade.
---